Brenig Therapeutics to Present AI-Enabled Design of a Brain-Penetrant NLRP3 Inhibitor at Keystone Symposia Neuroinflammation in Health and Disease
Summary
Brenig Therapeutics will present new data on its AI-enabled design of a brain-penetrant NLRP3 inhibitor at Keystone Symposia. The presentation highlights how Brenig and Expert Systems built a hybrid AI platform that combines structural biology, molecular dynamics, and machine learning to optimize potency, selectivity, safety, and brain exposure together. Brenig says the platform already supports two clinical-stage programs, including BT-409 and BT-267. The announcement reinforces Brenig’s positioning in neurodegenerative and neuroinflammatory drug discovery and shows how AI is shaping its pipeline development.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected